Logo image of HCWB

HCW BIOLOGICS INC (HCWB) Stock Price, Forecast & Analysis

USA - Nasdaq - NASDAQ:HCWB - US40423R2040 - Common Stock

2.11 USD
+0.07 (+3.43%)
Last: 12/5/2025, 12:57:59 PM

HCWB Key Statistics, Chart & Performance

Key Statistics
Market Cap5.70M
Revenue(TTM)2.84M
Net Income(TTM)-21.55M
Shares2.70M
Float2.11M
52 Week High41.2
52 Week Low1.84
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-28
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO2021-07-20
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


HCWB short term performance overview.The bars show the price performance of HCWB in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -20 -40 -60

HCWB long term performance overview.The bars show the price performance of HCWB in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of HCWB is 2.11 USD. In the past month the price decreased by -38.37%. In the past year, price decreased by -87.28%.

HCW BIOLOGICS INC / HCWB Daily stock chart

HCWB Latest News, Press Relases and Analysis

HCWB Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 23.87 398.69B
AMGN AMGEN INC 15.13 178.20B
GILD GILEAD SCIENCES INC 14.78 150.20B
VRTX VERTEX PHARMACEUTICALS INC 26.26 115.66B
REGN REGENERON PHARMACEUTICALS 16.02 75.76B
ALNY ALNYLAM PHARMACEUTICALS INC 895.23 60.32B
INSM INSMED INC N/A 43.91B
NTRA NATERA INC N/A 33.63B
BIIB BIOGEN INC 10.9 26.76B
UTHR UNITED THERAPEUTICS CORP 18.37 20.87B
INCY INCYTE CORP 16.05 20.22B
EXAS EXACT SCIENCES CORP N/A 19.20B

About HCWB

Company Profile

HCWB logo image HCW Biologics Inc. is a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases. The company is headquartered in Miramar, Florida and currently employs 36 full-time employees. The company went IPO on 2021-07-20. The company is focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases, such as cancer, cardiovascular diseases, diabetes, neurodegenerative diseases, autoimmune diseases, as well as other conditions. The company has developed a Tissue factOr-Based fusion (TOBI) discovery platform to generate designer, novel multi-functional fusion molecules with immunotherapeutic properties. Its lead product candidates include HCW9218 and HCW9302. HCW9218 is a clinical-stage bifunctional molecule that is designed to impact senescence by reducing senescent cells. The firm is prepared to progress HCW9218 in Phase II clinical trials for non-oncology indications.HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes. Its other product candidates include HCW9201, HCW9206, HCW11-006, and others.

Company Info

HCW BIOLOGICS INC

2929 N Commerce Pkwy, Miramar, Fl 33025

Miramar FLORIDA US

Employees: 36

HCWB Company Website

HCWB Investor Relations

Phone: 19548422024

HCW BIOLOGICS INC / HCWB FAQ

Can you describe the business of HCW BIOLOGICS INC?

HCW Biologics Inc. is a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases. The company is headquartered in Miramar, Florida and currently employs 36 full-time employees. The company went IPO on 2021-07-20. The company is focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases, such as cancer, cardiovascular diseases, diabetes, neurodegenerative diseases, autoimmune diseases, as well as other conditions. The company has developed a Tissue factOr-Based fusion (TOBI) discovery platform to generate designer, novel multi-functional fusion molecules with immunotherapeutic properties. Its lead product candidates include HCW9218 and HCW9302. HCW9218 is a clinical-stage bifunctional molecule that is designed to impact senescence by reducing senescent cells. The firm is prepared to progress HCW9218 in Phase II clinical trials for non-oncology indications.HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes. Its other product candidates include HCW9201, HCW9206, HCW11-006, and others.


Can you provide the latest stock price for HCW BIOLOGICS INC?

The current stock price of HCWB is 2.11 USD. The price increased by 3.43% in the last trading session.


Does HCWB stock pay dividends?

HCWB does not pay a dividend.


What is the ChartMill technical and fundamental rating of HCWB stock?

HCWB has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.


Would investing in HCW BIOLOGICS INC be a good decision?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on HCWB.


What is the market capitalization of HCWB stock?

HCW BIOLOGICS INC (HCWB) has a market capitalization of 5.70M USD. This makes HCWB a Nano Cap stock.


HCWB Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

HCWB Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to HCWB. Both the profitability and financial health of HCWB have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

HCWB Financial Highlights

Over the last trailing twelve months HCWB reported a non-GAAP Earnings per Share(EPS) of -28. The EPS decreased by -66.67% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -74.56%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%N/A
Sales Q2Q%-0.09%
EPS 1Y (TTM)-66.67%
Revenue 1Y (TTM)-57.71%

HCWB Forecast & Estimates

7 analysts have analysed HCWB and the average price target is 35.7 USD. This implies a price increase of 1591.94% is expected in the next year compared to the current price of 2.11.

For the next year, analysts expect an EPS growth of 16.94% and a revenue growth 368.22% for HCWB


Analysts
Analysts82.86
Price Target35.7 (1591.94%)
EPS Next Y16.94%
Revenue Next Year368.22%

HCWB Ownership

Ownership
Inst Owners1%
Ins Owners27.57%
Short Float %2.42%
Short Ratio0.48